Cardinal Health Guides FY27 EPS Above Target, Authorizes $5B Buyback
CAH sits 73% above its 52-week low of $137.75.
Summary
Cardinal Health posted a strong Q4 with GAAP EPS of $1.70 (up 70%) and non-GAAP EPS of $2.91 (up 40%), driven by broad-based operational strength across all five segments. The company issued FY27 adjusted EPS guidance of $12.40-$12.60, representing 13-15% growth and exceeding its long-term target. The board authorized a $5 billion increase to the share repurchase program, bringing total authorization to $6.4 billion, and declared a quarterly dividend of $0.5158 per share. Segment-level outlooks include 3-5% revenue growth in Pharmaceutical and Specialty Solutions and 2-4% in Global Medical Products and Distribution, with profit growth of 8-11% and $200-$220 million, respectively. The guidance incorporates the recently completed Strive Medical acquisition and the pending AdaptHealth Diabetes Health unit deal. This follows the earlier Q4 earnings release and adds concrete capital return and forward-looking details that materially strengthen the investment case.
At the time of this announcement, CAH was trading at $238.00 on NYSE in the Trade & Services sector, with a market capitalization of approximately $55.5B. The 52-week trading range was $137.75 to $244.87. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: dpa-AFX.